BioNTech sues Moderna - | the details:
BioNTech sues Moderna for patent infringement; shares of both companies remain stable.
deraktionaer.de/artikel/pharma-biotech/biontech-verklagt-moderna-die-details-20395822.html
Story Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
single unit of ownership in a corporation, mutual fund, or any other organization
News on this topic
BioNTech competitor Moderna is accelerating: FDA reverses course: Moderna shares are rising as the FDA is now reviewing the new mRNA flu vaccine ...
deraktionaer.de/artikel/pharma-biotech/biontech-konkurrent-moderna-gibt-kraeftig-gas-fda-macht-kehrtwende-20395719.html
Similar to This
Previous
Black day for BioNTech - | this is important now: BioNTech's stock fell by over 7% after a study setback with BNT113. The Phase 3 trial showed no better ...
deraktionaer.de/artikel/pharma-biotech/schwarzer-tag-fuer-biontech-das-ist-jetzt-wichtig-20416593.html
Bernd Förtsch on BioNTech: Resignation is overdue: Shareholder Bernd Förtsch sharply criticizes the events at the Corona superstar.
deraktionaer.de/artikel/aktien/bernd-foertsch-ueber-biontech-ruecktritt-ist-ueberfaellig-20409989.html
Moderna stock knows no bounds - | what's going on with BioNTech?: The stock has roughly tripled since the positive data was released.
deraktionaer.de/artikel/pharma-biotech/moderna-aktie-kennt-kein-halten-mehr-was-ist-mit-biontech-los-20409301.html
mRNA cancer vaccine: After soaring high, setback for Mainz-based BioNTech: After strong test data from its US competitor Moderna, BioNTech's stock price shot ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/mrna-krebsimpfstoff-nach-hoehenflug-rueckschlag-fuer-biontech-6171151
Paid articlePaywall BioNTech: mRNA Setback with Signal Effect - | Moderna's Fantasy Fizzles Out: Moderna Excites, BioNTech with Setback.
deraktionaer.de/artikel/pharma-biotech/biontech-mrna-rueckschlag-mit-signalwirkung-moderna-fantasie-verpufft-20407749.html
Paid articlePaywall
Not BioNTech or Moderna, but this company has delivered too!: Recently, biotechnology stocks in particular made headlines, but traditional pharmaceutical ...
wallstreet-online.de/nachricht/21283777-zahlen-stark-bewertung-billig-biontech-moderna-unternehmen-geliefert
Moderna kicks into high gear, BioNTech follows suit: Was this just the beginning?
deraktionaer.de/artikel/pharma-biotech/moderna-zuendet-den-turbo-biontech-zieht-nach-war-das-erst-der-auftakt-20407313.html
After Moderna's success: Attention turns to BioNTech - | this is what's planned now
deraktionaer.de/artikel/pharma-biotech/nach-moderna-erfolg-blick-richtet-sich-auf-biontech-das-ist-jetzt-geplant-20407208.html
Moderna reports breakthrough: Injection against cancer shows effect: The stock market and medical professionals react euphorically to Moderna's study results ...
rundschau-online.de/wirtschaft/moderna-meldet-durchbruch-spritze-gegen-krebs-zeigt-wirkung-1353895
Paid articlePaywall
Pharmaceuticals: Study success with cancer vaccine - | Moderna stock rises rapidly
handelsblatt.com/unternehmen/industrie/pharma-studienerfolg-bei-krebsimpfstoff-moderna-aktie-steigt-rasant/100248330.html
Paid articlePaywall
BioNTech Competitor: Moderna Shares Soar After Melanoma Study: U.S. biotech company Moderna reports positive results in a study on the treatment of melanoma ...
manager-magazin.de/unternehmen/moderna-aktien-mit-kursrallye-melanom-studie-zeigt-erste-erfolge-bei-krebstherapie-auch-biontech-profitiert-a-d206673a-4bb5-4aa6-9ce3-6a926ffb5f00
Barron's Aug 19
BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
barrons.com/articles/biontech-stock-moderna-cancer-vaccine-0925f6a6
Paid articlePaywall Moderna's share price soared: 177 percent increase - | Was this also the starting signal for BioNTech?
deraktionaer.de/artikel/deraktionaerplus/moderna-mit-kursfeuerwerk-177-prozent-plus-war-das-jetzt-auch-der-startschuss-fuer-biontech-20407124.html
Paid articlePaywall Forecast lowered: Vaccine stockpiles full in Germany, BioNTech deep in the red: Weak demand for the Covid-19 vaccine has resulted in significant losses and a ...
manager-magazin.de/unternehmen/pharma/biontech-umsatzprognose-gesenkt-wegen-voller-impfstofflager-a-f3f45a40-8696-4407-8f52-03a4cf7a3981
Moderna shares jump again, BioNTech also gains momentum - | what's going on?: Moderna shares rise. BioNTech also performs strongly. The reasons.
deraktionaer.de/artikel/deraktionaerplus/moderna-erneut-mit-kurssprung-auch-biontech-gibt-gas-was-ist-da-los-20394000.html
Paid articlePaywall
BioNTech rival with mega share price jump: Is the vaccine race starting all over again?
boerse-online.de/nachrichten/aktien/biontech-rivale-mit-mega-kurssprung-beginnt-das-impfstoff-rennen-von-vorne-20393447.html
Bayer sues COVID vaccine makers over mRNA technology: Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on ...
reuters.com/legal/litigation/bayer-sues-covid-vaccine-makers-over-mrna-technology-2026-01-06/
Patents: Corona vaccines - | Bayer sues BioNTech, Pfizer and Moderna: Bayer accuses several manufacturers of copying an old technology to produce mRNA vaccines ...
handelsblatt.com/unternehmen/industrie/patente-corona-impfstoffe-bayer-verklagt-biontech-pfizer-und-moderna/100189227.html
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths: Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a ...
investors.com/news/technology/moderna-biontech-covid-vaccines-deaths-myocarditis/
European Patent Office declares Moderna mRNA patent invalid: The European Patent Office declared a contested mRNA patent owned by Moderna invalid ...
reuters.com/business/healthcare-pharmaceuticals/biontech-says-european-patent-office-has-declared-moderna-patent-invalid-2023-11-21/
Key FactsEuropean Patent Office invalidates Moderna patent in vaccine dispute
Nov 21, 2023 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- The authority said its decision gave BioNTech and Pfizer a victory in the patent dispute between the vaccine makers.
- Moderna rejected the ruling and said it would file an appeal against the decision.
- Moderna shares were 2.3% lower in premarket trading on Wall Street after the announcement.
- Moderna sued BioNTech in Germany and other countries over allegedly copied mRNA technology it had patented long before 2019.
an important one, as we believe that this and others of Moderna's patents do not meet the requirements for grant and should never have been granted.— BioNTech, in a statement welcoming the EPO's decision
Next